


NEWSRELEASE

DELMEDICAINVESTMENTS September 7th 2007



Delmedica offers the private equity investor access to unique biotechnology opportunities that have the hallmarks of commercially successful ventures.



Delmedica is pleased to announce that Fortune Apex Developments Limited have achieved some significant milestones over the last few months which will go a long way to help them commercialise their MucoAd technology. The significant developments are listed below:

- Industrialisation of the bench scale process has been carried out with two industrial scale batches being produced in the facilities of Unifarm in Sofia, Bulgaria. The batches were both within the quality specs proving not only the scalability of the product but also its reproducibility. A paper is currently being prepared for submission to a major journal.
- An abstract entitled "**Difference in Tear Clearance Times between Standard Fluorescein Solution and a Novel Muco-adhesive Fluorescein Solution**" has been submitted for the AAAAI conference in Philadelphia. The conclusion was that a non-irritative methylcellulose solution with increased muco-adhesiveness delayed tear clearance assessed by fluorescein compared to standard, diagnostic fluorescein solution. The muco-adhesive solution was better tolerated.
- An abstract entitled "**The Effect of Delivering Fluorescein or Saccharine in a Novel Muco-adhesive Solution on Nasal Mucociliary Clearance**" has been submitted for the AAAAI conference in Philadelphia. The conclusion was Methylcellulose solutions with increased muco-adhesiveness (MucoAd) delayed nasal mucociliary clearance assessed by two separate measurements: time to taste saccharine (subjective) and fluorescein appearance in the pharynx (objective). The fluorescein muco-adhesive solution was better tolerated than control fluorescein.
- The Bio-Availability study for Metaclopramide in a MucoAd carrier has been initiated and is expected to be finished by December 2007. The results will be submitted for publication in top journals
- The NDA (new drug application) dossier for Xylometazoline has now been finished

Delmedica can also report some progress with the exhaled breath temperature device and the hiring of two new people to strengthen the team:

- 8 clinical studies are currently underway comparing the exhaled breath temperature (EBT) device with its major competitors (peak flow meter, NO measurement, and sputum measurement) as well as looking at the devices capabilities in determining the onset of Tuberculosis and other viral infections as well as looking at the influence of circadian rhythms on exhaled breath temperature.
- Initial results show that there appears to be a correlation with increased EBT and the onset of TB, further research is being carried out
- Delmedica is pleased to announce that Mr.Mourad Mankarios has joined the team as a non-executive director. Mourad has worked for more than 20 years for Philips Electronics in many senior roles throughout Europe, the Middle East and Africa. His last function at Philips was Chairman and CEO of Philips Electronics Singapore where he was responsible for 6200 people and several manufacturing sites. Mourad brings a host of qualities to DMI including his business acumen and his vast network of contacts at the highest level in Asia, Europe and the Americas.
- Discussions are currently ongoing with Venture Corporation (a Singapore listed company) to miniaturise the device and add ergonomics and electronics. This improved device will be marketed to the scientific community to increase the awareness of EBT as a diagnostic tool.
- Delmedica is pleased to announce that Dr.Tanya Kralimarkova has joined the team as Clinical Co-Ordinator to manage all the clinical work currently ongoing and to plan further work. Dr.Kralimarkova has already had experience working with the EBT device and has just gained her allergy specialty qualifications. We wish her success with her new job.
- - An article describing the EBT device and its operation has been published in the "Journal of Respiratory Medicine" in the October 2007 issue. The article is titled "Evaluation of a Simple, Potentially Individual Device for Exhaled Breath Temperature Measurement". The following link will take you to the abstract <http://dx.doi.org/10.1016/j.rmed.2007.06.005>.

DELMEDICA

Suite 2207-09 € Tower Two Lippo Centre € 89 Queensway € Admiralty € Hong Kong

www.delmedicainvestments.com